LAVA Therapeutics N.V. (LVTX) Tops Q1 EPS by 19c

LAVA Therapeutics N.V. (NASDAQ: LVTX) reported Q1 EPS of ($0.13), $0.19 better than the analyst estimate of ($0.32).

For earnings history and earnings-related data on LAVA Therapeutics N.V. (LVTX) click here.

You May Also Be Interested In

• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
• Sionna Therapeutics (SION) Reiterated at Market Outperform by Citizens: Readouts Upcoming
• FTI Consulting names Jerome Nyssen senior managing director in Australia